Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in vivo (LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2013-04-04 to 2013-07-05
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2013
Report date:
2013

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
Deviations:
no
Qualifier:
according to guideline
Guideline:
EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
Deviations:
no
Qualifier:
according to guideline
Guideline:
EPA OPPTS 870.2600 (Skin Sensitisation)
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Type of study:
mouse local lymph node assay (LLNA)

Test material

1
Chemical structure
Reference substance name:
tetrasodium 5-[(1E)-2-{4-[benzyl(ethyl)amino]-2-methylphenyl}diazen-1-yl]-8-[(1E)-2-{2,5-dimethyl-4-[(1E)-2-(3-sulfonatophenyl)diazen-1-yl]phenyl}diazen-1-yl]naphthalene-2-sulfonate 8-[(1E)-2-{4-[benzyl(ethyl)amino]-2-methylphenyl}diazen-1-yl]-5-[(1E)-2-{2,5-dimethyl-4-[(1E)-2-(3-sulfonatophenyl)diazen-1-yl]phenyl}diazen-1-yl]naphthalene-2-sulfonate
EC Number:
700-946-0
Molecular formula:
C40H35N7Na2O6S2
IUPAC Name:
tetrasodium 5-[(1E)-2-{4-[benzyl(ethyl)amino]-2-methylphenyl}diazen-1-yl]-8-[(1E)-2-{2,5-dimethyl-4-[(1E)-2-(3-sulfonatophenyl)diazen-1-yl]phenyl}diazen-1-yl]naphthalene-2-sulfonate 8-[(1E)-2-{4-[benzyl(ethyl)amino]-2-methylphenyl}diazen-1-yl]-5-[(1E)-2-{2,5-dimethyl-4-[(1E)-2-(3-sulfonatophenyl)diazen-1-yl]phenyl}diazen-1-yl]naphthalene-2-sulfonate
Test material form:
solid: particulate/powder

In vivo test system

Test animals

Species:
mouse
Strain:
CBA
Sex:
female
Details on test animals and environmental conditions:
- Full barrier in an air-conditioned room
- Temperature: 22 ± 3 °C
- Relative humidity: 55 ± 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: at least 10 x / hour
- Free access to Altromin 1324 maintenance diet for rats and mice (prescreen test and main study: lot no. 0902)
- Free access to tap water, sulphur acidified to a pH value of approx. 2.8 (drinking water, municipal residue control, microbiological controls at regular intervals)
- The animals were kept in groups of 5 animals in IVC cages, type II L, polysulphone cages on Altromin saw fibre bedding (prescreen test: lot no. 011012, main study: lot no. 240113)
- Certificates of food, water and bedding are filed at BSL BIOSERVICE
- Adequate acclimatisation period (at least five days) under laboratory conditions

Study design: in vivo (LLNA)

Vehicle:
other: 2% carboxymethylcellulose (CMC) in physiological saline 0.9% NaCl
Concentration:
Based on the results observed in the prescreen test the following test item concentrations were selected for the main study:
3%, 6% and 12.5% (w/v)

2% Carboxymethylcellulose (CMC) in physiological saline 0.9% NaCl served as negative control.
No. of animals per dose:
5 animals/dose group, 5 animals/control group
Details on study design:
Prescreen Test
Before the initiation of the prescreen test, a solubility test was performed to define the vehicle and the maximum concentration which is technically applicable to the animals.
The maximum technically applicable concentration of the test item in the vehicle was found to be 12.5% in 2% CMC in physiological saline 0.9% NaCl.
In order to determine the highest tolerated and not excessively irritant test concentration a prescreen test was performed which was conducted under the same conditions as the main study, except there was no assessment of lymph node proliferation. The mice were observed daily for any clinical signs of systemic toxicity or local irritation at the application site. Body weights were recorded pre-test and prior to termination. Both ears were observed for erythema and scored. Ear thickness measurements were performed on day 1 (pre-dose), day 3 (approximately 48 hours after the first dose) and day 6. Excessive local irritation was indicated by an erythema score ≥ 3 and/or ear swelling of ≥ 25%.
Two animals were treated by topical application with the test item on three consecutive days at a concentration of 12.5% (dissolved in 2% CMC in 0.9% NaCl) to the entire dorsal surface of each ear.
One further animal was treated with 100% CMC (undiluted) and served as negative control.
Immediately before the first application, approximately 48 hours after the first application and shortly before sacrificing the thickness of both ears of all animals was measured.
During this period also all clinical signs were recorded.
Cageside observations included spontaneous activity, lethargy, recumbent position, convulsions, tremors, apnoea, asphyxia, vocalisation, diarrhoea, changes in the skin and fur, eyes and mucous membranes (salivation, discharge).
Neither signs of systemic toxicity nor signs of irritation at the application site could be detected in any animal.
All animals showed the expected weight development, which includes a weight loss of up to 2 g throughout the duration of the prescreen test.

Main Study

Preparation of the Animals

The animals were randomly selected.
Identification was ensured by cage number and individual marking (tail).

Clinical Observation

Prior to the application and once a day thereafter all animals were observed in order to detect signs of toxicity, including dermal irritation at site of application.

Weight Assessment

The animals were weighed prior to the application and at the end of the test period (prior to the treatment with 3HTdR).

Dose Groups

3 test groups (3 different concentrations), 1 positive control (25% α-Hexylcinnamaldehyde in 2% CMC in 0.9% NaCl) and 1 negative control group (vehicle) were tested.

Test Regime

Topical Application
Immediately before the first application the thickness of both ears of all animals was measured. Each mouse was treated by topical application of 25 µL of the selected solution to the entire dorsal surface of each ear. A second measurement of the ear thickness of all animals was carried out approximately 48 hours after the first application.
Topical applications were performed once daily over three consecutive days.
Administration of 3H-Methyl Thymidine
Five days after the first topical application all mice were dosed with 20 µCi 3H-methyl thymidine by intravenous injection (tail vein) of 250 µL of 3H-methyl thymidine, diluted to a working concentration of 80 µCi/mL.

Preparation of Cell Suspension
Approximately 5 hours after the injection of 3H-methyl thymidine all mice were sacrificed by cervical dislocation. Shortly before sacrificing the thickness of the ears of all animals was measured for a third time. The draining auricular lymph nodes were excised, individually pooled for each animal (2 lymph nodes per animal) and collected in phosphate buffered saline (PBS). A single cell suspension of pooled lymph node cells was prepared by gentle mechanical disaggregation through polyamide gauze (200 mesh size). After washing the gauze with PBS the cell suspension was pelleted in a centrifuge. The supernatant was discarded and the pellets were resuspended with PBS. This washing procedure was repeated.
After the final wash each pellet was resuspended in approx. 1 mL 5% TCA at approx. 4° C for approximately 18 hours for precipitation of macromolecules. Each precipitate was once washed again, resuspended in 1 mL 5% TCA and 7 mL scintillation fluid was added. Then this solution was transferred into scintillation vials and stored at room temperature overnight.

Determination of Incorporated 3H-Methyl Thymidine
The 3H-methyl thymidine – incorporation was measured in a ß-counter and expressed as the number of disintegrations per minute (DPM). Similarly, background 3H-methyl thymidine levels were also measured (5% TCA). Determination of radioactivity was performed individually for each animal.

Evaluation of Results

The proliferative response of lymph node cells was expressed as the number of radioactive disintegrations per minute per lymph node (DPM/NODE) and as the ratio of 3H-methyl thymidine - incorporation into lymph node cells of test group animals relative to that recorded for control group animals (STIMULATION INDEX). Before DPM/NODE values were determined, background values were subtracted.
EC3 values, calculated concentrations which induce stimulation indices of three, are determined by linear interpolation {EC3=c+[(3-d)/(b-d)]x(a c)}, between two points of the stimulation indices axis, one above (a,b) and one below (c,d) the stimulation index of three. If all measured points are above or below the stimulation index of three, no EC3 value can be stated.
A substance is regarded as a 'sensitiser' in the LLNA if at least one concentration of the test item results in a 3-fold or greater increase in 3H-methyl thymidine - incorporation into lymph node cells of the test group animals, relative to that recorded for the lymph nodes of control group animals (Stimulation Index equal to or greater than 3.0).
Positive control substance(s):
hexyl cinnamic aldehyde (CAS No 101-86-0)
Statistics:
Outlier tests according to Dixon, Grubbs and Nalimov were performed for the values measured for the number of disintegrations per minute (DPM). If outliers were identified, these values were not included in the calculation of the stimulation indices. As at least four values per group are required for the evaluation of the results, the outlier test was not repeated to detect further outliers.

Results and discussion

Positive control results:
The stimulation index of the positive control (25% α-Hexylcinnamaldehyde in 2% CMC in in physiological saline 0.9% NaCl) was 8.0.

In vivo (LLNA)

Resultsopen allclose all
Parameter:
SI
Value:
3
Test group / Remarks:
12.5%
Parameter:
SI
Value:
2.4
Test group / Remarks:
6%
Parameter:
SI
Value:
1.5
Test group / Remarks:
3%
Parameter:
other: disintegrations per minute (DPM)
Remarks on result:
other: see Remark
Remarks:
Test Item Conc. [%] Animal number DPM DPM- mean back- ground Negative 100 16 742.0 726.0 Control 17 1141.0 1125.0 CMC (2%) 18 847.0 831.0 19 4457.0* n.d. 20 813.0 797.0 MV 885.8 869.8 SD 152.2 152.2 Positive 25 21 4079.0 4063.0 Control 22 9138.0 9122.0 α-Hexylcinnamaldehyde 23 6254.0 6238.0 in CMC (2%) 24 6879.0 6863.0 25 8511.0 8495.0 MV 6972.2 6956.2 SD 1786.3 1786.3 Acid Black RN 3333 3 1 870.0 854.0 2 2907.0** n.d. in CMC (2 %) 3 1724.0 1708.0 4 1346.0 1330.0 5 1483.0 1467.0 MV 1355.8 1339.8 SD 311.4 311.4 Acid Black RN 3333 6 6 2609.0 2593.0 7 1897.0 1881.0 in CMC (2 %) 8 2211.0 2195.0 9 2487.0 2471.0 10 1357.0 1341.0 MV 2112.2 2096.2 SD 450.3 450.3 Acid Black RN 3333 12.5 11 1935.0 1919.0 12 1432.0 1416.0 in CMC (2 %) 13 3311.0 3295.0 14 2993.0 2977.0 15 3513.0 3497.0 MV 2636.8 2620.8 SD 811.6 811.6 Background 16.0 Szinti and 20.0 TCA 14.0 16.0 14.0 MV 16.0 0.0 SD 2.2 * = outlier, failed Grubbs, Nalimov and Dixon; ** = outlier, failed Nalimov; n.d. = not determined

Any other information on results incl. tables

Table Ear Thickness – Preliminary Test (mm)

  Animal No. Measurement of Ear Thickness (mm)
Concentration Day 1 Day 3 Day 6
  left right left right left right
Acid Black RN 3333
12.5% in CMC (2%)
1 0.18 0.17 0.18 0.18 0.18 0.18
         
Acid Black RN 3333
12.5% in CMC (2%)
2 0.17 0.17 0.18 0.18 0.19 0.19
         
Negative Control
100% CMC (2%)
3 0.18 0.17 0.17 0.18 0.18 0.18

Table Absolute Body Weights – Preliminary Test (g)

Concentration Animal
No.
Start
of Study
End
of Study
Weight
Gain
Acid Black RN 3333
12.5% in CMC (2%)
1 22 22 0
         
Acid Black RN 3333
12.5% in CMC (2%)
2 23 23 0
         
Negative Control
100% CMC (2%)
3 21 22 1

Table Radioactive Determination of the Test Substance and Control Groups

POS CPM     Test Item Conc. [%] Animal number DPM DPM- mean back- ground DPM/ Node Stimu-lation Index
16 360.0     Negative 100 16 742.0 726.0 363.0  
17 553.0      Control   17 1141.0 1125.0 562.5  
18 410.0      CMC (2%)   18 847.0 831.0 415.5  
19 2174.0*         19 4457.0* n.d. n.d.  
20 395.0         20 813.0 797.0 398.5  
MV 429.5         MV 885.8 869.8 434.9 1.0
SD 73.6         SD 152.2 152.2 76.1  
21 1971.0     Positive 25 21 4079.0 4063.0 2031.5 4.7
22 4401.0     Control   22 9138.0 9122.0 4561.0 10.5
23 3030.0     α-Hexylcinnamaldehyde   23 6254.0 6238.0 3119.0 7.2
24 3326.0     in CMC (2%)   24 6879.0 6863.0 3431.5 7.9
25 4081.0         25 8511.0 8495.0 4247.5 9.8
MV 3361.8         MV 6972.2 6956.2 3478.1 8.0
SD 853.6         SD 1786.3 1786.3 893.1 2.1
1 425.0     Acid Black RN 3333 3 1 870.0 854.0 427.0 1.0
2 1409.0**         2 2907.0** n.d. n.d. n.d.
3 834.0     in CMC (2 %)   3 1724.0 1708.0 854.0 2.0
4 652.0         4 1346.0 1330.0 665.0 1.5
5 720.0         5 1483.0 1467.0 733.5 1.7
MV 657.8         MV 1355.8 1339.8 669.9 1.5
SD 149.3         SD 311.4 311.4 155.7 0.4
6 1258.0     Acid Black RN 3333 6 6 2609.0 2593.0 1296.5 3.0
7 917.0         7 1897.0 1881.0 940.5 2.2
8 1077.0     in CMC (2 %)   8 2211.0 2195.0 1097.5 2.5
9 1198.0         9 2487.0 2471.0 1235.5 2.8
10 653.0         10 1357.0 1341.0 670.5 1.5
MV 1020.6         MV 2112.2 2096.2 1048.1 2.4
SD 217.7         SD 450.3 450.3 225.1 0.5
11 935.0     Acid Black RN 3333 12.5 11 1935.0 1919.0 959.5 2.2
12 700.0         12 1432.0 1416.0 708.0 1.6
13 1607.0     in CMC (2 %)   13 3311.0 3295.0 1647.5 3.8
14 1454.0         14 2993.0 2977.0 1488.5 3.4
15 1689.0         15 3513.0 3497.0 1748.5 4.0
MV 1277.0         MV 2636.8 2620.8 1310.4 3.0
SD 389.8         SD 811.6 811.6 405.8 0.9
56 8.0     Background     16.0      
57 10.0     Szinti and     20.0      
58 7.0     TCA     14.0      
59 8.0           16.0      
60 7.0           14.0      
MV 8.0         MV 16.0 0.0 0.0 0.0
SD 1.1         SD 2.2      
* = outlier, failed Grubbs, Nalimov and Dixon; ** = outlier, failed Nalimov;   n.d. = not determined

Table Absolute Body Weights in g

Concentration Animal
No.
Start
of Study
End
of Study
Weight
Gain
  1 22 22 0
Acid Black RN 3333 2 20 22 2
3 % in CMC (2%) 3 20 21 1
  4 20 22 2
  5 20 21 1
         
  6 21 23 2
Acid Black RN 3333 7 20 21 1
6 % in CMC (2%) 8 21 23 2
  9 20 21 1
  10 19 20 1
         
  11 20 21 1
Acid Black RN 3333 12 22 24 2
12.5 % in CMC (2%) 13 21 22 1
  14 21 22 1
  15 19 21 2
         
  16 17 19 2
Negative Control 17 19 20 1
100% CMC (2%) 18 21 22 1
  19 21 22 1
  20 20 22 2
         
Positive Control
25% α-Hexyl-
cinnamaldehyde
in CMC (2%)
21 21 22 1
22 21 22 1
23 17 19 2
24 20 21 1
25 20 21 1

Table Clinical Observation

Time of Observation

Systemic Effects

Local Effects

Group 1, animals no. 1 – 5 / test item at a concentration of 3%in CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day3

nsf

nsf

Day4

nsf

nsf

Day5

nsf

nsf

Day6

nsf

nsf

Group 2, animals no. 6 – 10 / test item at a concentration of 6%in CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day3

nsf

nsf

Day4

nsf

nsf

Day5

nsf

nsf

Day6

nsf

nsf

Group 3, animals no. 11 – 15 / test item at a concentration of 12.5%in CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day3

nsf

nsf

Day4

nsf

nsf

Day5

nsf

nsf

Day6

nsf

nsf

Group 4, animals no. 16 – 20 / negative control100% CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day3

nsf

nsf

Day4

nsf

nsf

Day5

nsf

nsf

Day6

nsf

nsf

Group 5, animals no. 21 – 25 / positive control at a concentration of
25% α-Hexylcinnamaldehyde
in CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day3

nsf

nsf

Day4

nsf

nsf

Day5

nsf

nsf

Day6

nsf

nsf

nsf = no specific findings

Applicant's summary and conclusion

Interpretation of results:
other: classified as a Skin Sensitiser Cat.1, according to the CLP Regulation (EC) No.1272/2008
Conclusions:
As the stimulation index for the test concentration of 12.5% was 3, the EC3 value is 12.5. The measurement of the ear thickness did not reveal any relevant increase of the ear thickness in any dosage group.
The results of radioactivity determination were supported by the means of the ear thickness per group, which showed no relevant difference compared to the negative control.
Consequently, under the conditions of this study and according to OECD 429 the test item was found to be skin sensitizer.
Executive summary:

Based on the results of the prescreen test the test item was assessed for sensitising properties at concentrations of 3%, 6% and 12.5% (w/v), each diluted with 2% carboxymethylcellulose (CMC) in physiological saline 0.9% NaCl(v/v). The concentration of 12.5% in 2% CMC inphysiological saline 0.9% NaCl(v/v) was the maximum technically applicable concentration of the test item in the vehicle.


At the daily clinical observation the animals did not show any visible clinical symptoms and no case of mortality was observed.Species/strain:                     Mice, CBA/CaOlaHsd


Number of animals:            25/main test


Vehicle:                               2% carboxymethylcellulose in physiological saline 0.9% NaCl(v/v)


 


Summary Results


One of the three tested concentrations of the test item showed a stimulation index of 3.


The stimulation index at a concentration          of       3%      was     1.5


The stimulation index at a concentration          of       6%      was     2.4


The stimulation index at a concentration          of       12.5% was     3.0


 










































The mean ear thickness on



day 1



day 3



day 6



for the 3% test group was



0.16 mm



0.17 mm



0.17 mm



for the 6% test group was



0.16 mm



0.17 mm



0.18 mm



for the 12.5% test group was



0.18 mm



0.18 mm



0.18 mm



for the negative control group was



0.17 mm



0.18 mm



0.18 mm



for the positive control group was



0.18 mm



0.20 mm



0.20 mm



The stimulation index of the positive control (25% α-Hexylcinnamaldehyde in 2% CMC in physiological saline 0.9% NaCl) was 8.0 and therefore the test is considered to be valid.


 


  Conclusion


As the stimulation index for the test concentration of 12.5% was 3, the EC3 value is 12.5. The measurement of the ear thickness


did not reveal any relevant increase of the ear thickness in any dosage group.


The results of radioactivity determination were supported by the means of the ear thickness per group, which showed no relevant difference compared to the negative control.


Consequently, under the conditions of this study and according to OECD 429 the test item was found to be skin sensitizer.